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Abstract: Isoforms in the PDE3 family of cyclic nucleotide phosphodiesterases have important roles in
cyclic nucleotide-mediated signalling in cardiac myocytes. These enzymes are targeted by inhibitors
used to increase contractility in patients with heart failure, with a combination of beneficial and
adverse effects on clinical outcomes. This review covers relevant aspects of the molecular biology of
the isoforms that have been identified in cardiac myocytes; the roles of these enzymes in modulating
cAMP-mediated signalling and the processes mediated thereby; and the potential for targeting these
enzymes to improve the profile of clinical responses.
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1. Introduction
Cyclic nucleotide phosphodiesterases regulate intracellular signalling by hydrolysing cAMP
and/or cGMP. Enzymes in the PDE3 family of phosphodiesterases are dual-specificity enzymes
with high affinities for both cAMP and cGMP but much higher turnover rates for cAMP [1–3].
In cardiac muscle, these enzymes have been studied principally in the context of their role in regulating
cAMP-mediated signalling, and this is the focus of our review.
Several isoforms of PDE3 are expressed in cardiac myocytes, and PDE3 inhibitors are used
therapeutically to potentiate cAMP-mediated signalling in patients with heart failure. In the short
term, these agents have the desired action of increasing myocardial contractility, but their long-term
administration has been shown in several clinical trials to increase cardiovascular mortality [4–10].
This frustrating combination of beneficial and adverse effects of PDE3 inhibition presents a challenge
that remains to be solved. Here we review the function of PDE3 isoforms in cardiac muscle and raise
possibilities for targeting these isoforms so as to achieve more satisfying clinical outcomes.
2. The PDE3 Family of Cyclic Nucleotide Phosphodiesterases
Cyclic nucleotide phosphodiesterases comprise a superfamily of enzymes. As of now, more
than 50 mammalian isoforms have been described and classified into eleven gene families (PDE1
through PDE11) defined on the basis of sensitivity to pharmacologic inhibitors, kinetic activity,
and regulatory mechanisms [11]. PDE1, 2, 3, 10, and 11 hydrolyse both cAMP and cGMP; PDE4,
PDE7, and PDE8 selectively hydrolyse cAMP; and PDE5, PDE6, and PDE9 selectively hydrolyse
cGMP [11–13]. The N-terminal regulatory regions of phosphodiesterases contain sequences involved
in post-translational modifications and protein–protein interactions that target the enzymes to specific
functional compartments. Transcription start sites and alternative splicing lead to the generation of
multiple different isoforms of the same family.
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Enzymes in the PDE3 family are transcribed from two genes, PDE3A and PDE3B [14,15]. In the
case of PDE3A, three isoforms (some prefer the term ‘variants’) are generated by transcription from
alternative starts sites in the gene, yielding two mRNAs, as well as translation from alternative start
sites in the smaller mRNA (Figure 1) [16]. As a result of these N-terminal ‘deletions’, the amino-acid
sequences of these three isoforms differ only with respect to the lengths of their N-terminal sequences.
PDE3A1 (length: 996 amino acids; MW: 109,980), which is transcribed from an upstream start site and
translated from the second AUG in the PDE3A open reading frame—a possibly misleading term in
this case, as no isoform translated from the first AUG has been described—has an N-terminal sequence
containing hydrophobic loops that insert into intracellular membranes [17,18], as well as three sites
of phosphorylation that regulate protein–protein interactions [19–21]. PDE3A2 (length: 842 amino
acids; MW: 93,600) is transcribed from a downstream site in exon 1 and translated from the fourth
AUG in the PDE3A open reading frame; it lacks the most N-terminal phosphorylation site and the
transmembrane hydrophobic loops of PDE3A1. PDE3A3 (length: 659 amino acids; MW: 73,720) is
translated from the same mRNA as PDE3A2 and lacks all of the hydrophobic loops and the upstream
phosphorylation sites. These three isoforms are essentially indistinguishable with respect to their
basal catalytic activity and their sensitivity to catalytic site inhibitors [22]. At this time, only one
isoform of PDE3B (length: 1112 amino acids; MW: 124,333) has been described [15]. Like PDE3A1, its
N-terminal sequence contains hydrophobic loops (six for PDE3B, as compared to four for PDE3A1) and
phosphorylation sites, and its C-terminal sequence contains its catalytic region [23,24]. The sequence
of the catalytic region of PDE3B is >80% identical to that of PDE3A (both contain a 44-amino-acid
insert absent from other phosphodiesterase families), and its catalytic activity and inhibitor sensitivity
are similar to those of PDE3A; the remainder of the PDE3B sequence is 20–30% identical to that of
PDE3A [3].
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Figure 1. Structure and subcellular localisation of the PDE3 genes and their variants. Length in amino 
acids (aa) is provided at the top of the two PDE3 isoforms. PDE3A1 is translated from the second 
AUG codon of the open-reading frame found in the PDE3 mRNA. While the longest variant of 
PDE3A, PDE3A1, is mainly localised to the sarcoplasmic reticulum, PDE3A2 and PDE3A3 are found 
both in membranes and cytoplasm. PDE3B is mainly localised to plasma membrane invaginations 
known as T tubules. Coloured diamonds indicate phosphorylation sites. Selected PDE3-interacting 
proteins are listed where the precise binding sequences are known. Membrane-associated N-terminal 
hydrophobic regions 1 and 2 (NHR1 and 2) are depicted as loops. The catalytic domain, highly 
conserved between PDE3A and PDE3B, is indicated as a striped oval that includes the 44-amino-acid 
insert characteristic of PDE3 isoforms. 
Figure 1. Structure and subce lular localisation of the PDE3 genes and their variants. Length in amino
acids (aa) is provided at the top of t e t i f r s. PDE3A1 is translated from the second
AUG of the open-reading frame found in the PDE3 mRNA. While t e long st variant of PDE3A,
PDE3A1, is mainly localised to th sarcoplasmic reticulum, PDE3A2 and PDE3A3 are found b th in
membran s and cytoplasm. PDE3B is mainly localised t plasma membrane invaginatio s known as T
tubules. Coloured diam nds indicate phosphorylation sites. Selected PDE3-interacting proteins are
listed where the precise binding sequences are known. Membrane-associated N-terminal hydrophobic
regions 1 and 2 (NHR1 and 2) are depicted as loops. The catalytic domain, highly conserved between
PDE3A and PDE3B, is indicated as a striped oval that includes the 44-amino-acid insert characteristic
of PDE3 isoforms.
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3. Intracellular Localisation of PDE3A and PDE3B in Cardiac Myocytes and Their
Protein-Protein Interactions
Cyclic nucleotide-mediated signalling is highly compartmentalised in cardiac myocytes, and the
roles of individual phosphodiesterases in regulating cAMP- and cGMP-mediated signalling depend
upon their intracellular localisation. While PDE3A and PDE3B are both expressed in cardiac myocytes
(PDE3A more abundantly [25]), their intracellular distributions are distinct, with PDE3A localised
mainly to the sarcoplasmic reticulum and PDE3B to T tubules in proximity to mitochondria [26]
(Figure 1). PDE3 activity is also associated with nuclear membranes in cardiac myocytes [27], though
the specific isoforms have not been delineated. Furthermore, in subcellular preparations from cardiac
muscle, PDE3A1 is recovered solely in microsomal fractions, while PDE3A2 and PDE3A3 are recovered
in cytosolic as well as microsomal fractions [16]. This corresponds to studies in cells transfected with
PDE3A1- and PDE3B-derived constructs that show that the N-terminal hydrophobic loops in these
isoforms direct the insertion of these proteins into lipid membranes [17,18].
3.1. PDE3A
The precise intracellular localisation of PDE3 isoforms depends upon their interactions with anchoring,
scaffold, and adaptor proteins that recruit the enzyme to multiprotein signalling complexes [28–33].
Localised A-kinase anchoring proteins (AKAPs) tether protein kinase A (PKA) and other signalling
proteins—adenylyl cyclases, phosphatases, Epacs, PDEs and other effector molecules—to ‘signalosomes’
that allow selective phosphorylation of individual PKA substrates [31–34].
PDE3 has long been known to be associated with the sarcoplasmic reticulum of cardiac
myocytes [35,36]. Confocal microscopy studies more recently demonstrated co-localisation of PDE3A
with SERCA2, AKAP18, phospholamban, and desmin in the Z-bands of cardiac myocytes [37,38].
PDE3A was found to be a constituent of a multiprotein complex in the sarcoplasmic reticulum
containing AKAP18, phospholamban, and SERCA2 [38,39]. Addition of cAMP to microsomes from
human heart results in the phosphorylation of phospholamban by endogenous PKA; this leads
to a dissociation of phospholamban from SERCA2 and an increase in SERCA2 activity, and this
effect is potentiated by PDE3 inhibition [38] (Figure 2). Although PDE3 and PDE4 have both
been found to co-immunoprecipitate with AKAP-based signalosomes from human and mouse
myocardium and modulate effects of cAMP on L-type Ca2+ channels, ryanodine-sensitive Ca2+
channels, and SERCA2 [40–43], only PDE3 inhibition potentiates the PKA-mediated phosphorylation
of phospholamban and the consequent stimulation of SERCA2 activity [37]. The role of PDE3A in
modulating these effects is the likely explanation for the inotropic actions of PDE3 inhibition.
Furthermore, while PDE3 isoforms regulate the phosphorylation of other proteins through the
cAMP/PKA pathway, they are themselves substrates for protein kinases that modulate their catalytic
activity and protein–protein interactions [19,21,44–47]. The incorporation of PDE3A into the SERCA2
complex is an example. In co-immunoprecipitation experiments, phosphorylation of endogenous
PDE3A by PKA increases its interactions with SERCA2, caveolin-3, PKA regulatory subunit (PKARII),
PP2A, and AKAP18 [38]. Studies with recombinant proteins showed that phosphorylation of PDE3A
by PKA increased its co-immunoprecipitation with SERCA2a and AKAP18, suggesting that PDE3A
interacts directly with both proteins in a phosphorylation-dependent manner [38]. Deletion of the
N-terminal region of PDE3A1/PDE3A2 blocked PKA-induced phosphorylation of PDE3A and its
interaction with recombinant SERCA2. Of particular interest is the sequence RRRRSSS (amino acids
288–294 of the open reading frame, which are found only in PDE3A1), which provides three serines that
can be phosphorylated in vitro by different kinases under different conditions [19]. The introduction
of serine-to-alanine substitutions at S292-4 identified this sequence as the principal site responsible for
regulating the interactions of PDE3A1 with SERCA2 (Figure 1).
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Figure 2. Control of SERCA2 activity by PDE3A. Left panel: Under resting conditions, 
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cytoplasmic surface of the sarcoplasmic reticulum (double black line). Upon β-adrenergic receptor-
i r 2. Control f SERCA2 activity by PDE3A. Left panel: Under resting condition , phospholamban
(PLN) binds to SERCA2, who e activity it inhibits, as well as AKAP18δ on the cytoplasmic surface of t e
sarcoplasmic reticulum (double black l ne). Upon β-adrenergic receptor-stimulate cAMP produc ion,
PKA associated with AKAP18δ is activated and phosphorylates PLN (upper dotted line) and PDE3A1
(lower dotted line). This leads to the condition shown in the right panel, where phosphorylated PLN
detaches from SERCA2 and loses its inhibitory action. As a consequence, SERCA2-dependent Ca2+
uptake into the lumen of the sarcoplasmic reticulum is stimulated (encircled by the double black line).
At the same time, phosphorylated PDE3A1 binds to SERCA2 and increases its cAMP-hydrolytic activity,
which limits the extent to which β-adrenergic receptor-mediated signalling amplifies intracellular
Ca2+ cycling.
The absence of the S292-4 site from PDE3A2 and PDE3A3 establishes a PDE3A1-specific
mechanism for recruitment of PDE3A to the SERCA2 complex. The protein–protein interactions
of PDE3 isoforms are distinct in other ways as well, as has been described for the
phosphorylation-dependent interactions of PDE3A1, PDE3A2, and PDE3B with 14-3-3 [20,21,48–50].
The common sequence of PDE3A1 and PDE3A2 includes two 14-3-3-binding sites: S428, a PKC
site; and S312, a PKA/PKB (alternatively referred to Akt) site that resembles S318, a 14-3-3-binding
site in PDE3B [48,49] (Figure 1). In vitro, PDE3A1 is preferentially phosphorylated by PKA at S312,
whereas PDE3A2 is preferentially phosphorylated by PKC at S428; in preparations from human hearts,
PDE3A1 is phosphorylated primarily at S312, while PDE3A2 is phosphorylated primarily at S428 [50].
Furthermore, in transfected HEK293 cells, the phosphorylation-dependent interactomes of PDE3A1
and PDE3A2 are distinct [50]: PDE3A1 interacts with the 5-HT4(b) receptor, for example, while PDE3A2,
PDE3A3, and PDE3B do not [51]. These unique protein–protein interactions may provide opportunities
for isoform-specific targeting of the protein–protein interactions of individual isoforms.
In cardiac myocytes, PDE3A is also part of a multiprotein complex containing the unconventional
AKAP PI3Kγ [52]. While PI3Kγ directly binds the RII subunit of the PKA holoenzyme, how
PDE3A contacts the complex is still unclear, though a likely intermediate is the PI3Kγ interactor
p84/p87 [53]. Within this complex, PKA exerts a negative feedback regulation by phosphorylating
and activating the different associated PDE isoforms, including PDE3A [39]. In line with the role
of PDE3A (and PDE4A/B) in controlling SERCA2, loss of the scaffold function of PI3Kγ leads
to cAMP elevation and PKA-mediated hyperphosphorylation of phospholamban and L-type Ca2+
channels [39,54] (Figure 3, left panel). In hearts lacking PI3Kγ and subjected to pressure overload, this
effect causes cAMP elevation, contractile dysfunction, and increased mortality due to lethal arrhythmic
events such as sustained ventricular tachycardia [39] (Figure 3, right panel). Interestingly, this
abnormally increased cAMP accumulation appears to be selectively associated with signalling through
β-adrenergic receptors localised to T tubules [55]. This would suggest that the PI3Kγ PKA/PDE
complex is part of an ‘insulating’ system that blocks ‘leakage’ of cAMP from this compartment to
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the sarcoplasmic reticulum [39]. In heart failure, the expression of various elements of the PI3Kγ
PKA/PDE3A-containing complex change their stoichiometric ratios, with reduced expression of
p84/87 and coincident increased expression of PI3Kγ. This causes a dysfunctional cAMP regulation
potentially contributing to the increase in ventricular arrhythmias associated with heart failure [52].J. Cardiovasc. Dev. Dis. 2018, 5, x FOR PEER REVIEW  5 of 15 
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and associate with caveolin-3-enriched membrane subfractions containing cardioprotective proteins.
The recruitment of these cardioprotective proteins to these subfractions is PKA-dependent, and can be
reproduced in wild-type mice by PDE3 inhibition [26].
The nature of the localization signal that keeps PDE3B in such spatially and functionally
distinct cellular subdomains remains unknown. Various reports indicate that PDE3B can be
recruited to different multiprotein complexes with distinct properties. In adipocytes, for example,
treatment with insulin increases the phosphorylation of PDE3B associated with internal membranes,
promoting its interactions with IRS-1 (insulin receptor substrate-1), IRS-2, PI3K p85 (p85-subunit of
phosphoinositide 3-kinase), PKB (protein kinase B), HSP-90 (heat-shock protein 90), 14-3-3, and a
50 kD protein [46,47,56,59,60]. Conversely, treatment with β3-adrenergic receptor agonists increases
the phosphorylation of PDE3B associated with caveolin-1 in caveolae, promoting interactions with
β3-adrenergic receptors, PKA-RII (PKA regulatory subunit), and hormone-sensitive lipase [46,61].
Whether these associations also occur in cardiac myocytes is not yet clear. PDE3B has been reported
to weakly associate in a complex containing the unconventional AKAP PI3Kγ, especially with
overexpression in HEK293 cells [53,62]. Nonetheless, the significant effects on contractility and
rhythm detected in mice lacking PI3Kγ indicate that the determinant of the cardiac phenotype is the
ability of PI3Kγ to form more stable complexes with other phosphodiesterases, including PDE3A and
PDE4A/B [39].
Of note, however, is that PDE3B can be phosphorylated not only by PKA but also by PKB, the
main effector of the PI3K pathway. Although the weak interaction between PI3Kγ and PDE3B reported
in the heart awaits further experimental confirmation, severe reduction of the G protein-coupled
receptor-driven PI3K pathway by the concomitant loss of PI3Kγ and PI3Kβ has been shown to lead
to reduced PDE3B phosphorylation and activity in neurons [63]. Nonetheless, whereas the specific
association of PI3Kγ with β-adrenergic signalling in T tubules supports at least a spatial co-localisation
of both PI3K and PDE3B [39,53], experiments in knockout mice indicate that PI3Kγ and PDE3B might
be part of different functional complexes. On the other hand, the association of PI3Kγ with PKA
triggers a negative feedback loop where PKA phosphorylates and inhibits PI3Kγ itself. Interestingly,
loss of PDE3B in the heart leads to an unexpectedly strong elevation of cAMP [26], which likely remains
spatially confined due to the normal activity of the other phosphodiesterases. Whether this elevated
cAMP and PKA activity influences PI3Kγ catalytic activity and, indirectly, the PKB signalling axis is
yet to be determined. As enhanced PI3Kγ signalling is involved in the downregulation of β-adrenergic
receptor density on the cell surface and, generally, in cardiac myocyte decompensation under stress,
PDE3B inhibition could reduce a detrimental signal [64]. Inhibitors specifically distinguishing PDE3B
from PDE3A are not currently available, but specific targeting of PDE3B may be therapeutically useful
for ischaemia/reperfusion injury.
4. Inotropic Actions of PDE3A Inhibition
As discussed above, PDE3A is part of a multiprotein complex in the sarcoplasmic reticulum
through which phospholamban phosphorylation and SERCA2 activity are regulated, and PDE3
inhibition potentiates the stimulatory effects of cAMP on SERCA2 activity in microsomes from cardiac
muscle. These effects would be expected to increase contractility by increasing the amplitude of
intracellular Ca2+ transients. Experiments in mice with selective ablation of PDE3A and PDE3B
indicate that inotropic responses to PDE3 inhibition are attributable specifically to inhibition of PDE3A.
Phospholamban phosphorylation, SERCA2 activity, intracellular Ca2+ cycling, and contractility are
increased—and inotropic responses to PDE3 inhibition are eliminated—in Pde3a−/− mice; none of
these effects are observed in Pde3b−/− mice [37]. Furthermore, myocardial contractility in mice is
reduced when PDE3A1 is overexpressed [65]. Total intracellular cAMP levels are higher in Pde3b−/−
mice than in Pde3a−/− mice [26], indicating that this is not simply a ‘mass effect’ reflecting the higher
abundance of PDE3A relative to PDE3B in cardiac myocytes but is instead due to the specific functional
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consequences of the intracellular localisation of these isoforms. (A unique role of PDE3B in mitigating
reperfusion injury, discussed below, is further evidence along these lines [26].)
5. Pro-Apoptotic Actions of PDE3A Inhibition
PDE3 inhibition in rats and Pde3a ablation in mice lead to increases in the phosphorylation
of cAMP response element-binding protein (CREB) and consequent increases in the expression
of inducible cAMP early repressors (ICER’s), promoting apoptosis [66,67]. Inhibition of PDE3,
and especially of PDE3A, by milrinone might involve a phospho-CREB-induced increase in the
expression of ICER, with consequent apoptosis and myocardial pathological remodelling. Conversely,
there is evidence that increased PDE3A activity, achieved by overexpression in mice, reduces
ICER expression, increases Bcl-2 expression, and protects cardiac myocytes against apoptosis [65].
In fact, specific overexpression of myocardial PDE3A1 in transgenic mice confers protection during
ischaemia/reperfusion by decreasing cAMP signalling and phosphorylation of CREB, resulting in
decreased expression of ICER and reduced apoptosis [65]. PDE3 activity is associated with nuclear
membranes in cardiac myocytes [27], and it is possible that the activity localised to this region is
responsible for these pro-apoptotic changes in gene expression.
6. Pro-Hypertrophic Actions of PDE3A Inhibition
PDE3 inhibition has pro-hypertrophic actions in neonatal rat ventricular myocytes [68].
These effects are essentially reproduced by expression of a dominant-negative form of PDE3A2 induced
by a single amino acid substitution in the C-terminal region that renders the protein catalytically
inactive but otherwise intact [68]. This dominant-negative construct presumably functions as a
competitive inhibitor of the localising protein–protein interactions of the native protein to disrupt
its intracellular targeting; this is further evidence that the intracellular targeting of PDE3 isoforms
is as important as their catalytic activity. The antihypertrophic effect is especially interesting in
view of the description of a set of genetically unrelated missense mutations within a five-amino-acid
sequence in PDE3A that increase catalytic activity and lead to a syndrome of brachydactyly and
hypertension [69,70]. The hypertension is likely attributable to increased cGMP hydrolysis in vascular
smooth muscle; the resulting decrease in intracellular cGMP content would lead to a combination of
vasoconstriction and vessel wall hyperplasia. Despite the severe hypertension, however, patients with
this syndrome have strikingly low levels of cardiac hypertrophy [71]. This suggests that an increase in
PDE3A activity in cardiac myocytes may in fact be antihypertrophic, consistent with the benefits of
PDE3A1 overexpression with respect to pathologic remodelling in animal models discussed above [65].
7. Clinical Experience with PDE3 Inhibition in the Treatment of Heart Disease
With respect to cardiac disease, PDE3 has been of interest principally as a target for increasing
contractility in patients with heart failure, a condition in which decreases in β-adrenergic receptor
density and increases in Gαi and β-adrenergic receptor kinase activity in cardiac myocytes attenuate
cAMP generation lead to decreases in cAMP content, protein phosphorylation and the amplitude of
intracellular Ca2+ transients [72–81]. Inhibiting PDE3 has the effect of compensating to some extent for
these changes by blocking cAMP hydrolysis and potentiating cAMP-mediated signalling, leading to
an increase in myocardial contractility [82–88].
This short-term benefit, unfortunately, is outweighed by an increase in mortality from sudden
cardiac death of ~3% per year when these drugs are administered chronically [4–10]. The explanation
for this increase is unclear (though it seems restricted to patients in whom PDE3 inhibition is
used to treat contractile failure; no increase in mortality has been seen when the PDE3 inhibitor
cilostazol has been used to treat intermittent claudication [89]). Overexpression of SERCA2 in animal
models of ischaemia/reperfusion and chronic heart failure is anti-arrhythmic [90,91]. On the other
hand, an increase in the phosphorylation of L-type and ryanodine-sensitive Ca2+ channels may
be pro-arrhythmic [40–43]. It seems more probable, however, based on the fact that short-term
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administration of these agents is well tolerated, that mechanisms other than direct pro-arrhythmic
actions are involved, and that the pro-apoptotic and pro-hypertrophic effects of PDE3 inhibition
described above induce pathologic changes in the myocardium that increase the proclivity toward
malignant arrhythmias.
8. Selective Targeting of PDE3 Isoforms
The fact that PDE3A and PDE3B have different roles in cardiac myocytes, with PDE3A
controlling the pathways responsible for inotropic effects, raises the possibility that targeting PDE3A
selectively—or, perhaps even better, selectively targeting one of its three known variants—might
improve contractility without increasing sudden cardiac death (as noted above, PDE3A1 is restricted in
its distribution to intracellular membranes, so that its inhibition may be less likely to elicit pro-apoptotic
and pro-arrhythmic actions [16]). The catalytic activities, substrate affinities, and inhibitor sensitivities
of PDE3A1, PDE3A2, and PDE3A3 are identical, making it impossible to selectively target the active
sites of individual PDE3A variants [22]. The similarity of the PDE3B active site to the PDE3A active
site suggested that selectivity between these two proteins would also prove challenging. Recently,
however, investigators described a compound with a tenfold higher affinity for PDE3A relative to
PDE3B [92], so this supposition needs to be reconsidered. It is not obvious how targeting all PDE3A
isoforms without targeting PDE3B would confer a therapeutic advantage, however. To our knowledge,
no compound with a significantly higher affinity for PDE3B relative to PDE3A has been reported.
Another possibility is that of targeting individual isoforms not through their active sites but
through the protein–protein interactions by which they are localised intracellularly. As noted above,
PDE3A1 and PDE3A2 are recruited, by phosphorylation within their N-terminal sequences, to a
SERCA2/phospholamban/AKAP/PKA complex in the sarcoplasmic reticulum [37,93]. As a result of
this recruitment, PDE3 inhibition has a particularly pronounced effect in potentiating phospholamban
phosphorylation and increasing SERCA2 activity, leading to an increase in SERCA2 activity and
intracellular Ca2+ [38]. Experiments using recombinant proteins have demonstrated direct interactions
of PDE3A1 and PDE3A2 with both SERCA2 and AKAP18, and have shown that the interaction of
PDE3A1 with SERCA2 is dependent upon its phosphorylation at serine 293, a site within its unique
N-terminal extension (Figure 1) [38]. These findings indicate that the protein–protein interactions
of the PDE3A isoforms responsible for inotropic responses are highly individualised, opening an
avenue to isoform-selective targeting with a high degree of precision. In fact, this approach to
isoform-selective targeting—displacing PDE3A from specific multiprotein complexes—has the added
benefit of compartment selectivity, which is likely its most important advantage. Conventional PDE3
inhibitors target the enzyme regardless of its intracellular location; this can raise cAMP content globally
within the cell, resulting in a combination of pro-apoptotic, pro-hypertrophic, and inotropic [66–68].
Blocking the protein–protein interactions that integrate PDE3A into SERCA2 complexes could lead
to a selective increase in cAMP content in the vicinity of phospholamban and SERCA2 so as to
amplify intracellular Ca2+ cycling and increase contractility without the deleterious pro-arrhythmic,
pro-apoptotic, and pro-hypertrophic consequences (Figure 4).
On the other hand, the protein–protein interactions that localise PDE3B intracellularly may be
targets through which the cardioprotective effects of PDE3B ablation can be elicited without the
adverse pro-hypertrophic and pro-arrhythmic consequences of PDE3A inhibition. The feasibility of
this approach has been demonstrated in experiments using peptides that block the protein–protein
interactions of cyclic nucleotide phosphodiesterases. In one example, peptide-array scanning identified
a cell-permeant peptide based on a sequence in the N-terminus of PDE3B through which it is
incorporated into an Epac1/PI3Kγ complex in vascular endothelial cells. This peptide has been
shown to block the integration of PDE3B into this complex, increasing the activation of Epac1 by cAMP
and promoting intracellular tubule formation, cell adhesion, and cell spreading [94].
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Figure 4. Targeting PDE3A through protein–protein interactions. Conventional PDE3 inhibition
activates cAMP-mediated signalling in multiple intracellular compartments, leading possibly to a
combination of beneficial and adverse effects. Blocking the protein–protein interactions through which
PDE3A is integrated into the SERCA2 complex may stimulate intracellular Ca2+ cycling without the
adverse effects.
9. Conclusions
Several isoforms in the PDE3 family are expressed in cardiac myocytes, where they have important
roles regulating signalling pathways involved in inotropic, pro-apoptotic, and pro-hypertrophic
responses. Inhibition of myocardial PDE3 activity is an established therapeutic strategy for increasing
contractility in patients with heart failure, but an increase in sudden cardiac death in patients treated
chronically with existing PDE3 inhibitors has limited the benefits. Targeting individual PDE3A
isoforms in specific intracellular targets could potentially yield inotropic responses without this
adverse effect, while targeting PDE3B could have beneficial actions in ischaemia/reperfusion injury.
Recent discoveries open the possibility of selectively inhibiting PDE3A or PDE3B at their catalytic
sites or, probably more interestingly, of targeting their unique protein–protein interactions to yield
compartment-specific effects on intracellular signalling. Time will tell.
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Abbreviations
aa amino acid
AKAP A-kinase-anchoring protein
β2-AR β2-adrenergic receptor
cAMP Cyclic adenosine monophosphate
IRS Insulin-receptor substrate
NHR N-terminal hydrophobic region
PLN Phospholamban
PKA cAMP-dependent protein kinase
PKA-RII cAMP-dependent protein kinase regulatory subunit II
PKB (AKT) Protein kinase B
PKC Protein kinase C
PI3Kγ Phosphoinositide 3-kinase γ
PIP3 Phosphatidylinositol (3,4,5)-triphosphate
p110γ Phosphoinositide 3-kinase γ (PI3Kγ) catalytic subunit
p87 PI3Kγ regulatory subunit (also known as p87PIKAP p87-PI3K adapter protein)
SERCA2 Sarcoplasmic/endoplasmic reticulum calcium ATPase-2
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